While Mylan (MYL) has consistently made headlines for controversy over the pricing of its EpiPen, an auto-injector used to treat anaphylaxis and severe food allergies, there's more to the pricing of its competitor than meets the eye. Released today, Kaleo's Auvi-Q will cost insurers 9 times more than the Epipen. In response, Express Scripts (ESRX) , UnitedHealth Group (UNH) and Cigna (CI) will not cover the device.
More from Video
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.
Citi overcame a mixed print to send its stock surging on Monday.